Katrin Rupalla - 27 Jan 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Role
Director
Signature
/s/ Sonja Nelson, Attorney-in-Fact for Katrin Rupalla
Issuer symbol
N/A
Transactions as of
27 Jan 2023
Net transactions value
$0
Form type
4
Filing time
31 Jan 2023, 17:18:51 UTC
Previous filing
17 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMAM Stock Option (right to buy) Disposed to Issuer -200,000 -100% 0 27 Jan 2023 Ordinary Shares 200,000 $1.83 Direct F1, F2, F3
transaction AMAM Stock Option (right to buy) Award +200,000 200,000 27 Jan 2023 Ordinary Shares 200,000 $0.2800 Direct F1, F2, F3
transaction AMAM Stock Option (right to buy) Disposed to Issuer -105,000 -100% 0 27 Jan 2023 Ordinary Shares 105,000 $0.4300 Direct F2, F3, F4
transaction AMAM Stock Option (right to buy) Award +105,000 105,000 27 Jan 2023 Ordinary Shares 105,000 $0.2800 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent of the Ordinary Shares subject to the option vested on April 29, 2022, and the remainder vests in thirty-six equal monthly installments following such date.
F2 The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer.
F3 The option held by the reporting person was amended to reduce the exercise price.
F4 The Ordinary Shares subject to the option will vest on the earlier of (i) July 8, 2023, or (ii) the day immediately prior to the date of the next Annual Grant Date as defined in the Company's Non-Employee Director Compensation Policy.